A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. by Niedzwiecki, Donna et al.
UCSF
UC San Francisco Previously Published Works
Title
A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: 
Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Permalink
https://escholarship.org/uc/item/5t63v0xq
Journal
The oncologist, 22(1)
ISSN
1083-7159
Authors
Niedzwiecki, Donna
Hasson, Rian M
Lenz, Heinz-Josef
et al.
Publication Date
2017
DOI
10.1634/theoncologist.2016-0215
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
A Study of Thymidylate Synthase Expression as a Biomarker for
Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B)
9581 and 89803
DONNA NIEDZWIECKI,a RIAN M. HASSON,b HEINZ-JOSEF LENZ,d CYNTHIA YE,a MARK REDSTON,c SHUJI OGINO,c,e CHARLES S. FUCHS,e
CAROLYN C. COMPTON,f ROBERT J. MAYER,e RICHARD M. GOLDBERG,g THOMAS A. COLACCHIO,h LEONARD B. SALTZ,i ROBERT S. WARREN,j,*
MONICA M. BERTAGNOLLIb,*
aAlliance Statistics and Data Center and Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA;
Departments of bSurgery and cPathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA; dUniversity of Southern California
Norris Cancer Center, Los Angeles, California, USA; eDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts,
USA; fArizona State University, Phoenix, Arizona, USA; gThe Ohio State University, Columbus, Ohio, USA; hDepartment of Surgery,
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA; iMemorial Sloan Kettering Cancer Center, New York, New York, USA;
jDepartment of Surgery, University of California, San Francisco, San Francisco, California, USA
*Contributed equally.
Disclosures of potential conflicts of interest may be found at the end of this article.
Key Words. Colon cancer • Biomarkers • Adjuvant therapy • Thymidylate synthase • Microsatellite instability • Mismatch repair
deficiency
ABSTRACT
Purpose. Tumor levels of thymidylate synthase (TS), a target of
5-fluorouracil (5-FU)-based chemotherapy for colorectal cancer,
have been studied as a predictive or prognostic biomarker with
mixed results.
Patients and Methods. Tumor TS levels were prospectively
evaluated in two adjuvant therapy trials for patients with
resected stage II or III colon cancer. TS expression was deter-
mined by standard immunohistochemistry and by automated
quantitative analysis. Tumor mismatch repair deficiency (MMR-
D) and BRAF c.1799T>A (p.V600E) mutation status were also
examined. Relationships between tumor TS, MMR-D, and BRAF
mutation status, overall survival (OS), and disease-free survival
(DFS) were investigated in the subset of stage III patients.
Results. Patients whose tumors demonstrated high TS
expression experienced better treatment outcomes, with
DFS hazard ratio (HR)5 0.67, 95% confidence interval
(CI)5 0.53, 0.84; and OS HR5 0.68, 95% CI5 0.53, 0.88, for
high versus low TS expression, respectively. No significant
interaction between TS expression and stage was observed
(DFS: interaction HR5 0.94; OS: interaction HR5 0.94).
Tumors with high TS expression were more likely to demon-
strate MMR-D (22.2% vs. 12.8%; p5 .0003). Patients whose
tumors demonstrated both high TS and MMR-D had a 7-
year DFS of 77%, compared with 58% for those whose
tumors had low TS and were non-MMR-D (log-rank p5
.0006). Tumor TS expression did not predict benefit of a par-
ticular therapeutic regimen.
Conclusion. This large prospective analysis showed that high
tumor TS levels were associated with improved DFS and OS fol-
lowing adjuvant therapy for colon cancer, although tumor TS
expression did not predict benefit of 5-FU-based chemother-
apy.The Oncologist 2017;22:107–114
Implications for Practice: This study finds that measurement of tumor levels of thymidylate synthase is not helpful in assigning
specific adjuvant treatment for colorectal cancer. It also highlights the importance of using prospective analyses within treatment
clinical trials as the optimal method of determining biomarker utility.
INTRODUCTION
Adjuvant chemotherapy is an important component of treat-
ment for resectable colon cancer. However, although postoper-
ative adjuvant chemotherapy clearly improves survival in a
subset of patients with stage III colon cancer, many patients
derive no benefit, either because their disease recurs despite
adjuvant treatment or because their disease is effectively
Correspondence: Monica M. Bertagnolli, M.D., Department of Surgery, Brigham and Women’s Hospital, 75 Francis Street, Boston, Massachusetts
02115, USA. Telephone: 617-732-8991; e-mail: mbertagnolli@partners.org Received May 26, 2016; accepted for publication August 26, 2016;
published Online First on November 7, 2016.Oc AlphaMed Press 1083-7159/2016/$20.00/0 http://dx.doi.org/10.1634/theoncologist.2016-0215
TheOncologist 2017;22:107–114 www.TheOncologist.com Oc AlphaMed Press 2016
Gastrointestinal Cancer
treated by surgery alone. The benefit of adjuvant chemother-
apy is even more uncertain for patients with stage II disease, as
approximately 80% of these patients are cured by surgery.
Unfortunately, there are no markers for stage II colon cancer
that reliably define which patients will benefit from chemother-
apy, and there are no markers for stage III disease that distin-
guish patients for whom chemotherapy can be avoided.
Since its first demonstration of clinical benefit for adjuvant
therapy in 1993, 5-fluorouracil (5-FU) has been a mainstay of
colon cancer treatment, both in the adjuvant and advanced dis-
ease settings [1–3]. 5-FU inhibits the activity of thymidylate syn-
thase (TS;TYMS, HGNCID, HGNC:12441), an enzyme required
for generation of thymidine monophosphate (dTMP) through a
reaction converting 5,10-methylenetetrahydrofolate 1 deoxy-
uridine monophosphate (dUMP) to dihydrofolate 1 dTMP.
Lack of TS activity produces a deficit in dTMP that alters the
efficiency of DNA synthesis and repair by permitting G mispairs
and misincorporation of dUMP, which in turn causes DNA/RNA
strand breaks and cell death [4]. Theoretically, tumor TS levels
may influence therapeutic response to 5-FU because of this
relationship. However, although studies show an association
between tumor TS expression and outcomes following 5-FU-
based chemotherapy in a variety of patient cohorts, the avail-
able literature reports conflicting results.
Currently, the best-defined biomarkers for resectable colon
cancer are DNA mismatch repair (MMR) status and the pres-
ence of a BRAF c.1799T>A (p.V600E) mutation. In sporadic
tumors, DNA mismatch repair deficiency (MMR-D), also known
as microsatellite instability, is characterized by the inability to
repair single nucleotide mismatches due to loss of DNA mis-
match repair proteins by transcriptional silencing [5]. MMR-D is
present in approximately 25% of stage II and 16% of stage III
colon cancers. Patients with colon cancers that demonstrate
MMR-D have improved treatment outcomes [6–8]. BRAF is a
part of the RAS-RAF-MAP2K signaling pathway and BRAFmuta-
tions are present in 10%–20% of colon cancers. Of sporadic
colon cancers that are MMR-D, from 40%–50% also harbor a
BRAF mutation. The presence of a BRAF mutation is associated
with significantly worse patient survival in many studies [9].
Tumor TS analysis and determination of MMR status were
included as prospective secondary endpoints in two random-
ized, phase III trials for resectable colon cancer (C9581;
C89803). Study C89803, which enrolled patients with stage III,
was later amended to include an investigation of BRAF status.
The purpose of the current study was (1) to determine whether
tumor TS levels were associated with survival outcome or ben-
efit of 5-FU adjuvant therapy in patients with resectable colon
cancer and (2) to explore the impact of MMR and BRAF status
upon these relationships.
PATIENTS AND METHODS
Characteristics of Study Population
In the Alliance for Clinical Trials in Oncology (Alliance)/ Cancer
and Leukemia Group B (CALGB) protocol 89803 (C89803),
1,264 patients with stage III colon cancer were randomized fol-
lowing surgery to either adjuvant treatment with 5FU/LV or
5FU/LV and irinotecan (IFL) [10]. Alliance (CALGB) protocol
9581 (C9581) was a trial of 1,738 participants with stage II
colon cancer who received edrecolomab versus observation
alone [11]. The primary endpoint for both trials was overall sur-
vival (OS); disease-free survival (DFS) was a secondary end-
point. In both trials there was no difference in OS or
progression-free survival (PFS) among the patients randomized
to the standard versus experimental arms of each trial. These
protocols were approved by the institutional review board of
each treating center and all patients provided written informed
consent before participating. The Alliance (CALGB) Statistical
Center (Durham, NC) maintained the research database. Treat-
ment details and primary analysis results for these trials were
previously published [10, 11].
Determination of Biomarker Status
Paraffin blocks containing normal colon and tumor tissue were
processed as previously described [6]. Immunohistochemistry
(IHC) using the TS106 monoclonal antibody detected the pres-
ence of TS in primary tumor specimens. Cases were scored by
TS expression on a scale from 0 to 31, with a score of 0 or 11
describing “low”, and 21 and 31 representing “high,” accord-
ing to procedures described by Sinicrope et al. [12]. TS levels in
C89803 participants were also assessed using automated quan-
titative analysis (AQUA), which quantified TS nuclear localiza-
tion, cytoplasmic localization, the sum of the two, and the ratio
as continuous measurements. Tumor MMR status was assessed
using IHC to detect the presence of MLH1 and MSH2, as previ-
ously described [6]. Tumors lacking expression of either protein
were categorized as MMR-D and those exhibiting expression of
both proteins were determined mismatch repair intact (MMR-I).
Tumor BRAF mutational status was determined by polymerase
chain reaction and pyrosequencing spanning BRAF codon 600, as
previously described [9].
Statistical Analysis
The original C9581 and C89803 protocols presented overarch-
ing statistical analysis plans for correlative science biomarkers
including TS, MMR, and several other markers. Power esti-
mates were provided for multiple detectable hazard ratios and
proportions of available patient samples. In this study, 435
patients with stage II (25% of parent study C9581 cohort) and
463 patients with stage III (37% of parent study C89803 cohort)
with data on TS are available for analysis. With these sample
sizes, hazard ratios (TS high vs. low) of 0.52 and 0.58 are detect-
able with 80% power (2-sided a50.01 and 0.05, respectively)
in C9581, assuming 60% of patients exhibited TS high tumor
levels. Similarly, in C89803 hazard ratios of 0.61 and 0.66 were
detectable with 80% power (2-sided a50.01 and 0.05, respec-
tively) assuming 44% of patients exhibit TS high tumor levels.
The unplanned, pooled analysis allowed detection of 0.67 and
0.72 hazard ratios with 80% power (2-sided a50.01 and 0.05,
respectively) assuming 52% of patients with TS high tumor lev-
els. In all cases, power is less than 67% to detect interaction
DFS hazard ratios of 2.0 or less in magnitude with 307 events
observed.
OS was measured from study entry until death from any
cause; DFS was measured from study entry until documented
progression or death from any cause. Survival curves were esti-
mated using the Kaplan-Meier method. The log-rank test was
used to test associations between TS levels, combined TS and
MMR levels, and the survival outcomes (OS, DFS). Cox regres-
sion was used to analyze the following potentially prognostic
variables simultaneously with TS score and the combined
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variable based on TS and MMR for DFS and OS: study (C89803
vs. C9581), age (continuous), sex (male, female), race (white,
other), tumor location (left side, right side), tumor differentia-
tion (grades I, II; grades III, IV), performance status (0, 1, 2),
number of nodes sampled (continuous), T-stage (1, 2, 3, 4), and
extravascular invasion (present, absent). The interactions of TS
and combined TS and MMR score by study and treatment
within study were also considered. In addition, the proportional
hazards assumption was assessed using a time-dependent Cox
model. The maximal v2 method was used to determine the
optimal cut point for the four TS variables measured by AQUA
(nuclear, cytoplasmic, total, and ratio) relative to association
with DFS and OS. Fisher’s exact test and the v2 test were used
to test associations between categorical variables.
RESULTS
High Tumor TS Expression Is Associated With Improved
DFS and OS in Patients With Resectable Colon Cancer
TS levels were assessed in 898 of 3,002 patients with resectable
colon cancer enrolled on either C9581 (1,738 stage II patients;
435 analyzed by IHC) or C89803 (1,264 stage III; 463 analyzed
by IHC and 416 by AQUA). Reporting recommendations for
tumor MARKer prognostic studies REMARK diagrams for each
trial describing the distributions of cases used for marker analy-
ses are provided in supplemental online Figure 1A, 1B. Patient
and tumor characteristics were comparable between the entire
study cohort and patients with without analyzed samples and
between studies (Table 1). Of the 898 patients studied, 52%
(n5 471) were determined to have high TS levels. This propor-
tion of high expression cases is consistent with that of other
IHC studies [12–14]. A significantly lower proportion of stage III
patients exhibited high TS, 44% (203/463) versus 60% for stage
II, p< .0001.
Patients whose tumors demonstrated high TS expression
experienced better survival outcomes for both DFS (hazard
ratio [HR]5 0.67; 95% confidence interval [CI]5 0.53, 0.84; log-
rank p5 .0005; Fig. 1A) and OS (HR5 0.68; 95% CI5 0.53,
0.88; log-rank p5 .002; Fig. 1B). Seven-year DFS was 0.71 ver-
sus 0.60 for high versus low TS expression; 7-year OS was 0.76
versus 0.66, respectively. The proportional hazards assumption
was not violated and no significant interaction between TS
expression and stage (treatment with 5-FU) was observed (DFS:
interaction HR5 0.94; 95% CI, 0.58,1.51; pinteraction5 0.80; OS:
interaction HR5 0.94; 95% CI5 0.56,1.58; pinteraction5 0.83).
Figure 1C and 1D illustrate DFS and OS, respectively, by TS sta-
tus and study. The association between tumor TS expression
and DFS remained significant upon multivariable analysis
including known prognostic factors (p5 .03; Table 2). TS status
was not significant in a multivariable analysis of OS.
High Tumor TS Expression in the Subsets of Patients by
Stage (With and Without 5-FU-Based Adjuvant
Chemotherapy)
We examined outcomes among the patients with stage III dis-
ease (C89803) who received adjuvant chemotherapy containing
5-FU. For patients with high tumor TS expression, 7-year DFS
was 0.63, compared with 0.54 for those with low TS expression
(Table 3; Fig. 2A). Similarly, 7-year OS was 0.70 versus 0.61 for
patients with high versus low TS expression (Fig. 2B).
For AQUA, single measurements were available for 40
patients and averages were computed when multiple measure-
ments were available (149 patients with 2 measurements, 226
with 3 measurements, and 1 patient with 6 measurements;
Figure 1. Relationship between tumor TS expression level and treatment outcome in the full cohort. (A, B): DFS and OS, respectively, by
TS (IHC) expression level for both studies combined. (C, D): DFS and OS, respectively, by TS (IHC) expression level and study.
Abbreviations: DFS, disease-free survival; IHC, immunohistochemistry; OS, overall survival; TS, thymidylate synthase.
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total n5 416). Optimal cut points were obtained for each
AQUA measurement and survival outcome (DFS, OS). Results
using the AQUA method were consistent with those achieved
by IHC, although the distribution of high- versus low-expressing
cases was different (e.g., high nuclear expression in 70%; Table
3). Tumor TS expression was also examined as a predictive fac-
tor for benefit of IFL versus standard 5-FU/LV. By either IHC or
AQUA methods, TS expression did not predict differential bene-
fit to treatment with IFL. Supplemental online Figure 2a, 2b
illustrates DFS and OS for TS by IHC and study treatment in
C89803.
For the stage II patients on C9581, none of whom were
treated in the adjuvant setting with 5-FU, 7-year DFS was 0.76
versus 0.69, and OS was 0.81 versus 0.74 for high versus low TS
expression, respectively (Table 3; Fig. 2C, 2D). No significant
interactions between TS expression levels and treatment (edre-
colomab versus observation) were found for either DFS or OS
(supplemental online Fig. 2c, 2d).
Combination of TS Expression and Tumor MMR Status
May Permit Stratification of Patients Into High- and
Low-Recurrence Risk and Survival Categories
Previous analyses of C89803 and C9581 showed that tumor
MMR-D was a marker of favorable outcome [6, 15]. For the
combined cohort, patients whose tumors demonstrated MMR-
D achieved better 5-year DFS (76% vs. 67%; log-rank p< .001)
compared with those whose tumors were MMR-I. We there-
fore studied TS status in relationship to MMR status in the
Table 1. Patient and tumor characteristics by study
89803 89803 89803 9581 9581
Characteristic Entire cohort TS by IHC TS by AQUA Entire cohort TS by IHC
No. of patients 1,264 463 416 1,738 435
Age, years, mean (range) 59.9 (21–85) 59.8 (24–83) 60.03 (24–85) 64.1 (24–90) 64.4 (34–89)
Sex
Male 702 (55.54%) 254 (54.86%) 228 (54.81%) 901 (51.84%) 233 (53.56%)
Female 562 (44.46%) 209 (45.14%) 188 (45.19%) 837 (48.16%) 202 (46.44%)
Treatment
FU/LV or edrecolomab 629 (49.76%) 228 (49.24%) 218 (52.4%) 865 (49.77%) 234 (53.79%)
IFL or observation 635 (50.24%) 235 (50.76%) 198 (47.6%) 873 (50.23%) 201 (46.21%)
Tumor location
Proximal 715 (57.85%) 254 (55.46%) 237 (57.66%) 1048 (60.97%) 259 (59.54%)
Distal 521 (42.15%) 204 (44.54%) 174 (42.34%) 671 (39.03%) 176 (40.46%)
Tumor differentiation
Well-differentiated 71 (5.74%) 24 (5.23%) 21 (5.1%) 146 (8.49%) 36 (8.31%)
Moderately differentiated 862 (69.68%) 331 (72.11%) 295 (71.60%) 1305 (75.92%) 325 (75.06%)
Poorly or undifferentiated 304 (24.58%) 104 (22.66%) 96 (23.30%) 268 (15.59%) 72 (16.63%)
No. of positive nodes, mean (range) 3.5 (0–29) 3.5 (1–23) 3.5 (1–24) N/A N/A
Nodal ratio, mean (range) 0.30 (0.30–1.33) 0.29 (0.01–1.00) 0.31 (0.01–1.00) N/A N/A
Nodes sampled, mean (range) 14.4 (1–99) 14.7 (1–99) 14.9 (1–68) 14.4 (0–99) 13.9 (0–59)
7-year DFS (95% CI) 0.57 (0.54, 0.60) 0.58 (0.53, 0.62) 0.62 (0.57, 0.66) 0.74 (0.71, 0.76) 0.73 (0.69, 0.77)
7-year OS (95% CI) 0.65 (0.62–0.67) 0.65 (0.60, 0.69) 0.69 (0.64, 0.73) 0.79 (0.77, 0.81) 0.78 (0.74, 0.82)
Abbreviations: AQUA, automated quantitative analysis; CI, confidence interval; DFS, disease-free survival; FU/LV, 5-fluorouraciland leucovorin; IFL,
FU/LV and irinotecan; IHC, immunohistochemistry; OS, overall survival; TS, thymidylate synthase.
Table 2. Multivariable analysis of disease-free survival endpointa
Parameter (Cohort) df HR 95% CI Chi-square p value
TS by IHC (C898031 C9581)
TS score (high) 1 0.77 (0.61, 0.97) .03
Study (C9581) 1 0.48 (0.37, 0.62) <.0001
Age (>65 years) 1 1.03 (1.01, 1.03) .001
Performance status (1; 2) 1 1.37 (1.07, 1.75) .01
No. of nodes sampled (more) 1 0.98 (0.96, 0.99) .01
T stage (T4) 1 1.58 (1.19, 2.08) .001
Extravascular invasion present 1 1.62 (1.12, 2.33) .009
aPotentially prognostic variables included in the model were TS score (high vs. low); study (C9581 vs. C89803), age (continuous), sex (male,
female), race (white, other), tumor location (left side, right side), tumor differentiation (grades I, II; grades III, IV), performance status (0,1,2), num-
ber of nodes sampled (continuous),T-stage (1, 2, 3, 4), and extravascular invasion (present, absent); n5 869 with 296 events.
Abbreviations: CI, confidence interval; HR, hazard ratio; IHC, immunohistochemistry; TS, thymidylate synthase.
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current analysis. Tumors with high TS expression were more
likely to demonstrate MMR-D (22.2% vs. 12.8%; p5 .0003).
No significant interaction between TS and MMR status was
observed (HR5 0.82; 95% CI5 0.42, 1.59, for DFS; HR5 0.62,
95% CI5 0.42, 1.35, for OS). In multivariable analyses including
both TS and MMR, TS remained significantly related to DFS but
not OS, whereas MMR remained significantly related to OS but
not DFS (data not shown).
We further studied the combined variable defined by TS
and MMR. Significant differences were found in both DFS (log-
rank across four subgroups p5 .0006) and OS (log-rank across
four subgroups p5 .002) across the four subgroups (Fig. 3A,
3B). For the combined cohort, patients whose tumors demon-
strated both high TS and MMR-D had a 7-year DFS of 77%,
compared with 58% for those whose tumors had low TS and
were MMR-I. Seven-year OS was comparable (77%, 77%, 80%)
for patients with high TS and MMR-D tumors, high TS and
MMR-I tumors, and low TS and MMR-D tumors, respectively,
compared with 64% for patients whose tumors had low TS and
were MMR-I.
A significant interaction was found between the combined
TS/MMR variable and study for both DFS and OS (DFS:
pinteraction5 0.002; OS: pinteraction5 0.02). For DFS, the best and
worst subgroups among stage II patients were TS high/MMR-D
and TS low/MMR-I, respectively. Intermediate responses were
observed for patients whose tumors were TS high/MMR-I or TS
low/MMR-D (Fig. 4). Among patients with stage III disease, a
finding of MMR-D did not provide a DFS benefit regardless of
TS level. These results are consistent with a potential detrimen-
tal effect of a 5-FU treatment regimen in patients with MMR-D
tumors. No distinct pattern was observed for OS.
Impact of BRAF on TS Expression and Tumor MMR
Status in Stage III Colon Cancer
Previous results from C89803 showed that BRAF mutation is
associated with inferior survival, with a 5-year OS of 0.63 versus
0.75 (p5 .015) for cohorts with or without tumor mutations,
respectively [9]. In the current study, characterization of TS,
MMR, and BRAF was available for 328 stage III patients, and we
explored the effect of BRAF mutation on treatment outcomes
for this subset. Although the numbers were small, the results
indicate that the beneficial effect of having a tumor with high TS
expression andMMR-D status was negated by the presence of a
BRAFmutation. Among 26 cases that were high TS and MMR-D
and had data on BRAF, 10 also had BRAF V600E-mutant tumors.
In this subset, the 7-year OS5 0.875,95% CI5 0.58,0.96, versus
OS5 0.50,95% CI5 0.18,0.75, for those with and without BRAF
mutation. Because of the overall small number of cases and low
mutation rate for BRAF mutation (16%), the contribution of
BRAFmutation was not explored further.
DISCUSSION
Because of its relationship to DNA synthesis and its role as a
target of 5-FU activity, TS protein expression and mRNA levels
Table 3. Outcome by TS expression level
DFS OS
n 7-yr DFS 95% CI p value HR 95% CI 7-yr OS 95% CI p value HR 95% CI
Patients receiving 5-FU-based chemotherapy on Study C89803: tumor TS expression measured by immunohistochemistrya
High TS 203 0.63 (0.56, 0.69) 0.05b 0.75 (0.56, 1.01) 0.70 (0.63, 0.76) .09b 0.76 (0.55, 1.01)
Low TS 260 0.54 (0.47, 0.60) 0.61 (0.55, 0.67)
Patients receiving 5-FU-based chemotherapy on Study C89803: tumor TS expression measured by AQUAc
Nuclear .006d 0.55 (0.40, 0.76) .30d 0.67 (0.47, 0.96)
6.05 126 0.50 (0.40, 0.58) 0.63 (0.54, 0.71)
>6.05 290 0.67 (0.61, 0.72) 0.67 (0.61, 0.72)
Cytoplasmic .01d 0.58 (0.42, 0.80) .23d 0.64 (0.42, 0.97)
4.71 117 0.50 (0.40, 0.59) 0.67 (0.61, 0.72)
>4.71 299 0.66 (0.60, 0.71) 0.76 (0.67, 0.83)
Total .009d 0.57 (0.41, 0.78) .11d 0.61 (0.41, 0.89)
5.16 123 0.51 (0.41, 0.59) 0.65 (0.58, 0.71)
>5.16 293 0.66 (0.60, 0.71) 0.76 (0.69, 0.82)
Ratio .25d 1.93 (1.01, 3.66) .23d 1.93 (1.01, 3.66)
1.04 43 0.76 (0.60, 0.86) 0.87 (0.72, 0.94)
>1.04 373 0.60 (0.55, 0.65) 0.67 (0.62, 0.72)
Patients not treated with 5-FU, Study 9581: tumor TS expression by immunohistochemistrya
High TS 268 0.76 (0.70, 0.81) .07b 0.71 (0.49, 1.04) 0.81 (0.75, 0.86) .11b 0.72 (0.48, 1.08)
Low TS 167 0.69 (0.61, 0.76) 0.74 (0.66, 0.80)
aHigh TS 5 21, 31; low TS5 0,11.
bLog-rank p value.
cVariables except for the ratio are normalized by 1,000.
dExact Gauss method.
Abbreviations: AQUA, automated quantitative analysis; CI, confidence interval; DFS, disease-free survival; 5-FU, 5-fluorouracil; HR, hazard ratio; OS,
overall survival; TS, thymidylate synthase.
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have been extensively studied in colon cancer patients treated
in both metastatic and adjuvant settings. Most, but not all,
studies of patients receiving 5-FU-based chemotherapy for
metastatic disease showed that high TS levels were associated
with inferior survival [16–19]. To date, results from the adjuvant
setting have been mixed [13, 20, 21]. This prospective study
from two large cooperative group trials of stage II and III colon
cancers showed that TS status provided independent prognos-
tic information, with improved outcomes for patients with high
TS expression. This study also achieved the same result with
both a standard IHC technique and AQUA in patients with stage
III/high risk stage II disease treated with 5-FU-containing regi-
mens. Results reported for AQUA based on the optimal cut
points will need to be validated. The prospective nature and
uniform treatment of patients in this study, together with a rel-
atively large sample size, lend further validity to these results.
Prospective biomarker studies included in randomized clini-
cal trials provide the best assessment of biomarker utility. For
TS, the only large-scale, prospective data available are from an
adjuvant colorectal cancer trial involving continuous intraportal
vein infusion of 5-FU that was conducted in 200 hospitals
throughout China [13]. This study, reported in 2006 by Popat
Figure 3. Relationship between TS expression level and MMR status combined and treatment outcome in the full cohort. (A, B): DFS and
OS, respectively, by TS expression level and MMR status measured by immunohistochemistry in the full cohort.
Abbreviations: DFS, disease-free survival; MMR, mismatch repair; MMR-D, mismatch repair deficiency; MMR-I, mismatch repair intact;
OS, overall survival; TS, thymidylate synthase.
Figure 2. Relationship between tumor TS expression level and treatment outcome within study. DFS and OS, respectively, by TS expres-
sion level in C89803 (A, B) and C9581 (C, D).
Abbreviations: DFS, disease-free survival; OS, overall survival; TS, thymidylate synthase.
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et al., differed from ours in that, of the 779 stage II and III cases
studied, 59% were rectal cancers. Although the overall propor-
tion of TS high cases was similar to ours (58%), the results failed
to show prognostic significance, with a 5-year OS of 0.59 versus
0.56 for cases with high and low TS expression, respectively
(p5 .6). In another notable study, Sinicrope et al. [12] per-
formed a retrospective analysis of TS expression in tumors
from 313 patients with colon cancer treated on five random-
ized 5-FU-based adjuvant chemotherapy trials conducted by
the North Central Cancer Treatment Group. This study also
addressed the relationship between tumor TS expression and
MMR status. The proportion of cases that were TS high (55%)
and MMR-D (19%) were similar to those reported here. In con-
trast to our results, these investigators found that tumor MMR
status and TS expression were unrelated and that TS failed to
provide prognostic information. The methods for biomarker
assessment were the same in both this study and ours. The dif-
ferent result presented here may be explained by the prospec-
tive nature and larger, more uniform patient cohorts from
C89803 and C9581. Limitations of this study, however, include
the low power to test interaction effects (e.g., TS level by stage)
and the inability to distinguish between stage of disease and
treatment with or without 5FU/LV.
Currently, the best-defined prognostic biomarkers for
resectable colon cancer are tumor MMR status and the pres-
ence of a BRAFmutation. An extensive body of literature shows
that tumors that are MMR-D exhibit distinct clinical and patho-
logical features, including more common presence of poorly
differentiated histology with abundant tumor-infiltrating lym-
phocytes, location in the proximal colon, and occurrence in
female patients. Following adjuvant colon cancer treatment,
MMR-D tumors clearly demonstrate improved DFS and OS [5,
6]. BRAF is a part of the RAS-RAF-MAP2K signaling pathway.
BRAF mutations are present in 10%–20% of colon cancers and,
like MMR-D, are associated with proximal tumor location. In
contrast, however, the presence of a BRAFmutation was associ-
ated with significantly worse patient survival in several large
studies, including C89803 [9, 22, 23]. Of sporadic colon cancers
that are MMR-D, 40%–50% also harbor BRAF mutation. The
effect of a BRAF mutation appears to be additive to that of
MMR-D, with outcomes that are worst for patients whose
tumors are both BRAF-mutant and MMR-I, intermediate for
cases that are BRAF-mutant and MMR-D, and best for those
that are BRAF-wild type and MMR-D [9, 22, 23].
It remains unclear whether patients whose tumors are
MMR-D experience poorer response to 5-FU-based chemother-
apy, although large retrospective studies suggest that this may
be the case [24–26]. Although this study shows that tumor TS
levels do not predict response to 5-FU-based chemotherapy, it
does contribute to the mounting evidence that 5-FU treatment
is ineffective or detrimental for patients with MMR-D tumors.
CONCLUSION
The presence of a high tumor TS expression is associated with
increased survival in patients with stage II and III colon cancer.
This biomarker does not predict benefit to 5-FU-based chemo-
therapy in the trials studied here, and therefore is of limited
use in assigning specific treatment in the adjuvant setting.
However, treatment with 5-FU appeared to affect the relation-
ship between the combination of tumor TS expression and
MMR-D status and survival outcomes.
Figure 4. Relationship between TS expression level and MMR status combined and treatment outcome within study. DFS and OS, respec-
tively, by TS Expression Level and MMR status measured by immunohistochemistry in C89803 (A, B) and C9581 (C, D).
Abbreviations: DFS, disease-free survival; MMR, mismatch repair; MMR-D, mismatch repair deficiency; MMR-I, mismatch repair intact;
OS, overall survival; TS, thymidylate synthase.
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